Jump to content

Furosemide

From Wikipedia, the free encyclopedia
"Lasix" redirects here. For the method of eye surgery, seeLASIK.

Furosemide
Clinical data
Pronunciation/fjʊˈroʊsəˌmaɪd/
Trade namesLasix, Furoscix, others
Other namesFurosemide
AHFS/Drugs.comMonograph
MedlinePlusa682858
License data
Pregnancy
category
  • AU:C
Routes of
administration		oral,intravenous,intramuscular,subcutaneous
ATC code
Legal status
Legal status
  • AU:S4(Prescription only)
  • UK:POM(Prescription only)
  • US:WARNING[1]Rx-only[2][3]
  • In general: ℞ (Prescription only)
Pharmacokineticdata
Bioavailability43–69%
Protein binding91–99%
MetabolismLiverandkidneyglucuronidation
Onset of action30 to 60 min (PO), 5 min (IV)[4]
Eliminationhalf-lifeup to 100 minutes
ExcretionKidney(66%),bile duct(33%)
Identifiers
  • 4-Chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.000.185Edit this at Wikidata
Chemical and physical data
FormulaC12H11ClN2O5S
Molar mass330.74g·mol−1
3D model (JSmol)
  • o1cccc1CNc(cc2Cl)c(C(=O)O)cc2S(=O)(=O)N
  • InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)checkY
  • Key:ZZUFCTLCJUWOSV-UHFFFAOYSA-NcheckY
(verify)

Furosemide,sold under the brand nameLasixamong others, is aloop diureticmedication used to treatedemadue toheart failure,liver scarring,orkidney disease.[4]Furosemide may also be used for the treatment ofhigh blood pressure.[4]It can be takenintravenouslyororally.[4]When given intravenously, furosemide typically takes effect within five minutes; when taken orally, it typically metabolizes within an hour.[4]

Common side effects includeorthostatic hypotension(decrease inblood pressurewhile standing, and associatedlightheadedness),tinnitus(ringing in the ears), andphotosensitivity(sensitivity to light).[4]Potentially serious side effects includeelectrolyte abnormalities,low blood pressure,andhearing loss.[4]It is recommended thatserumelectrolytes(especiallypotassium), serumCO2,creatinine,BUNlevels, andliverandkidneyfunctioning be monitored in patients taking furosemide. It is also recommended to be alert for the occurrence of any potentialblood dyscrasias.[4]Furosemide is a type ofloop diureticthat works by decreasing the reabsorption of sodium by the kidneys.[4]Common side effects of furosemide injection include hypokalemia (low potassium level), hypotension (low blood pressure), and dizziness.[5]

Furosemide was patented in 1959 and approved for medical use in 1964.[6]It is on theWorld Health Organization's List of Essential Medicines.[7]In the United States, it is available as ageneric medication.[4]In 2022, it was the 24th most commonly prescribed medication in the United States, with more than 23million prescriptions.[8][9]In 2020/21 it was the twentieth most prescribed medication in England.[10]It is on theWorld Anti-Doping Agency's banned drug list due to concerns that it may mask other drugs.[11]It has also been used in race horses for the treatment and prevention ofexercise-induced pulmonary hemorrhage.[12][13]

Medical uses

[edit]
Furosemide (Lasix) for injection.

Furosemide is primarily used for the treatment ofedema,but also in some cases ofhypertension(where there is also kidney or heart impairment).[14]It is often viewed as a first-line agent in most people with edema caused bycongestive heart failurebecause of its anti-vasoconstrictor and diuretic effects.[4][15]Compared with furosemide, however,torasemide(aka "torsemide" ) has been demonstrated to show improvements to heart failure symptoms, possibly lowering the rates of rehospitalisation associated with heart failure, with no difference in risk of death.[16][17][18]Torsemide may also be safer than furosemide.[19][20]Providing self-administered subcutaneous furosemide has been found to reduce hospital admissions in people with heart failure, resulting in significant savings in healthcare costs.[21][22]

Furosemide is also used for livercirrhosis,kidney impairment,nephrotic syndrome,in adjunct therapy forswelling of the brainorlungswhere rapiddiuresisis required (IVinjection), and in the management of severehypercalcemiain combination with adequate rehydration.[23]

Kidney disease

[edit]

In chronic kidney diseases withhypoalbuminemia,furosemide is used along with albumin to increase diuresis.[24]It is also used along with albumin innephrotic syndrometo reduce edema.[25]

Other information

[edit]

Furosemide is mainly excreted by tubular secretion in the kidney. In kidney impairment, clearance is reduced, increasing the risk of adverse effects.[4]Lower initial doses are recommended in older patients (to minimize side-effects) and high doses may be needed inkidney failure.[26]It can also cause kidney damage; this is mainly by loss of excessive fluid (i.e., dehydration), and is usually reversible.[citation needed]

Furosemide acts within 1 hour of oral administration (after IV injection, the peak effect is within 30 minutes). Diuresis is usually complete within 6–8 hours of oral administration, but there is significant variation between individuals.[27]

Adverse effects

[edit]

Furosemide also can lead togoutcaused byhyperuricemia.Hyperglycemiais also a common side effect.[28][29][30]

The tendency, as for all loop diuretics, to cause low serum potassium concentration (hypokalemia) has given rise to combination products, either with potassium or with thepotassium-sparing diureticamiloride(Co-amilofruse). Other electrolyte abnormalities that can result from furosemide use include hyponatremia, hypochloremia, hypomagnesemia, and hypocalcemia.[31]

In the treatment of heart failure, many studies have shown that the long-term use of furosemide can cause varying degrees ofthiamine deficiency,sothiaminesupplementation is also suggested.[32]

Furosemide is a known ototoxic agent generally causing transient hearing loss but can be permanent. Reported cases of furosemide induced hearing loss appeared to be associated with rapid intravenous administration, high dosages, concomitant renal disease and coadministration with other ototoxic medication.[33][34]However, a recently reported longitudinal study showed that participants treated with loop diuretics over 10 years were 40% more likely to develop hearing loss and 33% more likely of progressive hearing loss compared to participants who did not use loop diuretics.[35]This suggests the long-term consequences of loop diuretics on hearing could be a more significant than previously thought and further research is required in this area.

Other precautions include: nephrotoxicity, sulfonamide (sulfa) allergy, and increases free thyroid hormone effects with large doses.[36]

Interactions

[edit]

Furosemide has potential interactions with these medications:[37]

Potentially hazardous interactions with other drugs:

Mechanism of action

[edit]
Main article:Loop diuretic

Furosemide, like other loop diuretics, acts by inhibiting the luminalNa-K-Cl cotransporterin thethick ascending limbof theloop of Henle,by binding to the Na-K-2Cl transporter, thus causing more sodium, chloride, and potassium to be excreted in the urine.[38]

The action on the distal tubules is independent of any inhibitory effect on carbonic anhydrase or aldosterone; it also abolishes the corticomedullary osmotic gradient and blocks negative, as well as positive,free water clearance.Because of the large NaCl absorptive capacity of the loop of Henle, diuresis is not limited by development of acidosis, as it is with the carbonic anhydrase inhibitors.[citation needed]

Additionally, furosemide is a noncompetitive subtype-specific blocker of GABA-A receptors.[39][40][41]Furosemide has been reported to reversibly antagonize GABA-evoked currents of α6β2γ2receptors at μM concentrations, but not α1β2γ2receptors.[39][41]During development, the α6β2γ2receptor increases in expression in cerebellar granule neurons, corresponding to increased sensitivity to furosemide.[40]

Pharmacokinetics

[edit]
  • Molecular weight (daltons) 330.7
  • %Bioavailability47 – 70%
    • Bioavailability with end-stage renal disease 43 – 46%[42][43]
  • % Protein binding 91 – 99[44]
  • Volume of distribution (L/kg) 0.07 – 0.2[45][46]
    • Volume of distribution may be higher in patients with cirrhosis or nephrotic syndrome[45]
  • Excretion
    • % Excreted in urine (% of total dose) 60 – 90[45][46]
    • % Excreted unchanged in urine (% of total dose) 53.1 – 58.8[47]
    • % Excreted in feces (% of total dose) 7 – 9[27]
    • % Excreted in bile (% of total dose) 6 – 9[46]
  • Approximately 10% is metabolized by the liver in healthy individuals, but this percentage may be greater in individuals with severe kidney failure[46]
  • Renal clearance (mL/min/kg) 2.0[45]
  • Elimination half-life (hrs) 2[44]
    • Prolonged in congestive heart failure (mean 3.4 hrs)[45][48]
    • Prolonged in severe kidney failure (4 – 6 hrs)[49]and anephric patients (1.5 – 9 hrs)[46]
  • Time to peak concentration (hrs)
    • Intravenous administration 0.3[50]
    • Oral solution 0.83[44]
    • Oral tablet 1.45[44]

The pharmacokinetics of furosemide are apparently not significantly altered by food.[51]

No direct relationship has been found between furosemide concentration in the plasma and furosemide efficacy. Efficacy depends upon the concentration of furosemide in urine.[27]

Names

[edit]

Furosemide is theINNandBAN.[52]The previous BAN was frusemide.

Brand names under which furosemide is marketed include: Aisemide, Apo-Furosemide, Beronald, Desdemin, Discoid, Diural, Diurapid, Dryptal, Durafurid, Edemid, Errolon, Eutensin, Farsiretic, Flusapex, Frudix, Frusemide, Frusetic, Frusid, Fulsix, Fuluvamide, Furantril, Furesis, Furix, Furo-Puren, Furon, Furosedon, Fusid.frusone, Hydro-rapid, Impugan, Katlex, Lasilix, Lasix, Lodix, Lowpston, Macasirool, Mirfat, Nicorol, Odemase, Oedemex, Profemin, Rosemide, Rusyde, Salix, Seguril, Teva-Furosemide, Trofurit, Uremide, and Urex.

Veterinary uses

[edit]
Furosemide for feline use

The diuretic effects are put to use most commonly in horses to prevent bleeding during a race. In the United States of America, pursuant to the racing rules of most states, horses that bleed from the nostrils (exercise-induced pulmonary hemorrhage) three times are permanently barred from racing. Sometime in the early 1970s, furosemide's ability to prevent, or at least greatly reduce, the incidence of bleeding by horses during races was discovered accidentally. Clinical trials followed, and by decade's end, racing commissions in some states in the USA began legalizing its use on race horses. In 1995,New Yorkbecame the last state in the United States to approve such use, after years of refusing to consider doing so.[53]Some states allow its use for all racehorses; some allow it only for confirmed "bleeders". Its use for this purpose is still prohibited in many other countries.[citation needed]

Furosemide is also used in horses for pulmonary edema, congestive heart failure (in combination with other drugs), and allergic reactions. Although it increases circulation to the kidneys, it does not help kidney function, and is not recommended for kidney disease.[54]

It is also used to treat congestive heart failure (pulmonary edema, pleural effusion, and/or ascites) in cats and dogs.[55]

Horses

[edit]

Furosemide is injected eitherintramuscularlyorintravenously,usually 0.5-1.0 mg/kg twice/day, although less before a horse is raced. As with many diuretics, it can causedehydrationandelectrolyte imbalance,including loss ofpotassium,calcium,sodium,andmagnesium.Excessive use of furosemide will most likely lead to ametabolic alkalosisdue tohypochloremiaandhypokalemia.The drug should, therefore, not be used in horses that are dehydrated or experiencing kidney failure. It should be used with caution in horses with liver problems or electrolyte abnormalities. Overdose may lead to dehydration, change in drinking patterns and urination, seizures, gastrointestinal problems, kidney damage, lethargy, collapse, and coma.

Furosemide should be used with caution when combined with corticosteroids (as this increases the risk of electrolyte imbalance), aminoglycoside antibiotics (increases risk of kidney or ear damage), and trimethoprim sulfa (causes decreased platelet count). It may also cause interactions with anesthetics, so its use should be related to the veterinarian if the animal is going into surgery, and it decreases the kidneys' ability to excreteaspirin,so dosages will need to be adjusted if combined with that drug.

Furosemide may increase the risk ofdigoxintoxicity due to hypokalemia.

It is recommended that furosemide not be used during pregnancy or in a lactating mare, as it has been shown to be passed through the placenta and milk in studies with other species. It should not be used in horses withpituitary pars intermedia dysfunction(Equine Cushing's Disease).

Furosemide is detectable in urine 36–72 hours following injection. Its use is restricted by most equestrian organizations.

US major racetracks ban the use of furosemide on race days.[56]

References

[edit]
  1. ^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)".nctr-crs.fda.gov.FDA.Retrieved22 October2023.
  2. ^"Lasix- furosemide tablet".DailyMed.26 January 2021.Retrieved18 November2022.
  3. ^"Furoscix- furosemide injection 80 mg/ 10 ml injection".DailyMed.21 October 2022.Retrieved18 November2022.
  4. ^abcdefghijkl"Furosemide".The American Society of Health-System Pharmacists.Archivedfrom the original on 19 November 2015.Retrieved23 October2015.
  5. ^"Coronavirus (COVID-19) Update: December 22, 2020".U.S. Food and Drug Administration(Press release). 22 December 2020.Retrieved22 December2020.Public DomainThis article incorporates text from this source, which is in thepublic domain.
  6. ^Fischer J, Ganellin CR (2006).Analogue-based Drug Discovery.John Wiley & Sons. p. 458.ISBN9783527607495.
  7. ^World Health Organization(2023).The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023).Geneva: World Health Organization.hdl:10665/371090.WHO/MHP/HPS/EML/2023.02.
  8. ^"The Top 300 of 2022".ClinCalc.Archivedfrom the original on 30 August 2024.Retrieved30 August2024.
  9. ^"Furosemide Drug Usage Statistics, United States, 2013 - 2022".ClinCalc.Retrieved30 August2024.
  10. ^"PCA England".NHS Business Services Authority.Retrieved8 August2022.
  11. ^"World Anti-doping Code International Standard Prohibited List 2022"(PDF).2022. p. 12.Archived(PDF)from the original on 10 July 2022.Retrieved27 July2022.
  12. ^Sullivan S, Hinchcliff K (April 2015). "Update on exercise-induced pulmonary hemorrhage".The Veterinary Clinics of North America. Equine Practice.31(1): 187–198.doi:10.1016/j.cveq.2014.11.011.PMID25770069.
  13. ^Hinchcliff KW, Couetil LL, Knight PK, Morley PS, Robinson NE, Sweeney CR, et al. (2015)."Exercise induced pulmonary hemorrhage in horses: American College of Veterinary Internal Medicine consensus statement".Journal of Veterinary Internal Medicine.29(3): 743–758.doi:10.1111/jvim.12593.PMC4895427.PMID25996660.
  14. ^"Furosemide".The American Society of Health-System Pharmacists.Archivedfrom the original on 17 March 2011.Retrieved3 April2011.
  15. ^King KC, Goldstein S (2021)."Congestive Heart Failure And Pulmonary Edema".StatPearls.Treasure Island (FL): StatPearls Publishing.PMID32119444.Retrieved8 May2021.
  16. ^Täger T, Fröhlich H, Seiz M, Katus HA, Frankenstein L (July 2019). "READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials".Heart Failure Reviews.24(4): 461–472.doi:10.1007/s10741-019-09771-8.PMID30874955.S2CID77394851.
  17. ^Miles JA, Hanumanthu BK, Patel K, Chen M, Siegel RM, Kokkinidis DG (June 2019). "Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis".Journal of Cardiovascular Medicine.20(6): 379–388.doi:10.2459/JCM.0000000000000794.PMID30950982.S2CID96436158.
  18. ^Abraham B, Megaly M, Sous M, Fransawyalkomos M, Saad M, Fraser R, et al. (January 2020). "Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure".The American Journal of Cardiology.125(1): 92–99.doi:10.1016/j.amjcard.2019.09.039.PMID31699358.S2CID207937875.
  19. ^Roush GC, Kaur R, Ernst ME (January 2014). "Diuretics: a review and update".Journal of Cardiovascular Pharmacology and Therapeutics.19(1): 5–13.doi:10.1177/1074248413497257.PMID24243991.S2CID21204143.
  20. ^Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. (March 2015)."A reappraisal of loop diuretic choice in heart failure patients".American Heart Journal.169(3): 323–333.doi:10.1016/j.ahj.2014.12.009.PMC4346710.PMID25728721.
  21. ^Dahiya G, Bensimhon D, Goodwin MM, Mohr JF, Alexy T (August 2022)."From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion".Structural Heart.6(4): 100076.doi:10.1016/j.shj.2022.100076.PMC10242578.PMID37288336.
  22. ^Khan WJ, Arriola-Montenegro J, Mutschler MS, Bensimhon D, Halmosi R, Toth K, et al. (November 2023). "A novel opportunity to improve heart failure care: focusing on subcutaneous furosemide".Heart Failure Reviews.28(6): 1315–1323.doi:10.1007/s10741-023-10331-4.PMID37439967.S2CID259843357.
  23. ^Rossi S, ed. (2004).Australian Medicines Handbook 2004(5th ed.). Adelaide, S.A.:Australian Medicines HandbookPty Ltd.ISBN978-0-9578521-4-3.
  24. ^Kitsios GD, Mascari P, Ettunsi R, Gray AW (April 2014). "Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis".Journal of Critical Care.29(2): 253–259.doi:10.1016/j.jcrc.2013.10.004.PMID24268626.
  25. ^Duffy M, Jain S, Harrell N, Kothari N, Reddi AS (October 2015)."Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies".Cells.4(4): 622–630.doi:10.3390/cells4040622.PMC4695849.PMID26457719.
  26. ^"British National Formulary".Retrieved9 November2018.
  27. ^abcPonto LL, Schoenwald RD (May 1990). "Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I)".Clinical Pharmacokinetics.18(5): 381–408.doi:10.2165/00003088-199018050-00004.PMID2185908.S2CID32352501.
  28. ^Li Q, Li X, Kwong JS, Chen H, Sun X, Tian H, et al. (June 2017)."Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements".BMJ Open.7(6): e014928.doi:10.1136/bmjopen-2016-014928.PMC5623447.PMID28645962.
  29. ^Li Q, Li X, Wang J, Liu H, Kwong JS, Chen H, et al. (August 2019)."Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements".BMJ Open.9(8): e026677.doi:10.1136/bmjopen-2018-026677.PMC6720466.PMID31446403.
  30. ^Han Y, Cao Y, Han X, Di H, Yin Y, Wu J, et al. (July 2023)."Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey".J Transl Med.21(1): 463.doi:10.1186/s12967-023-04307-z.PMC10339518.PMID37438830.
  31. ^Oh SW, Han SY (June 2015)."Loop Diuretics in Clinical Practice".Electrolyte & Blood Pressure.13(1): 17–21.doi:10.5049/EBP.2015.13.1.17.PMC4520883.PMID26240596.
  32. ^Katta N, Balla S, Alpert MA (July 2016)."Does Long-Term Furosemide Therapy Cause Thiamine Deficiency in Patients with Heart Failure? A Focused Review".The American Journal of Medicine.129(7): 753.e7–753.e11.doi:10.1016/j.amjmed.2016.01.037.PMID26899752.
  33. ^Favrelière S, Delaunay P, Lebreton JP, Rouby F, Atzenhoffer M, Lafay-Chebassier C, et al. (June 2020). "Drug-induced hearing loss: a case/non-case study in the French pharmacovigilance database".Fundamental & Clinical Pharmacology.34(3): 397–407.doi:10.1111/fcp.12533.PMID31912913.S2CID210087413.
  34. ^Gallagher KL, Jones JK (November 1979). "Furosemide-induced ototoxicity".Annals of Internal Medicine.91(5): 744–745.doi:10.7326/0003-4819-91-5-744.PMID496112.
  35. ^Joo Y, Cruickshanks KJ, Klein BE, Klein R, Hong O, Wallhagen MI (February 2020). Newman A (ed.)."The Contribution of Ototoxic Medications to Hearing Loss Among Older Adults".The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences.75(3): 561–566.doi:10.1093/gerona/glz166.PMC7328195.PMID31282945.
  36. ^"UpToDate".www.uptodate.com.Retrieved6 November2018.
  37. ^Brand name:Lasix - Generic name: FurosemidePrescription Drug Information, Side Effects - PDRHealth
  38. ^Dowd FJ, Johnson B, Mariotti A (3 September 2016).Pharmacology and Therapeutics for Dentistry - E-Book.Elsevier Health Sciences. pp. 324–326.ISBN9780323445955.Retrieved4 November2017.
  39. ^abKorpi ER, Kuner T, Seeburg PH, Lüddens H (February 1995). "Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor".Molecular Pharmacology.47(2): 283–289.PMID7870036.
  40. ^abTia S, Wang JF, Kotchabhakdi N, Vicini S (June 1996)."Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit".The Journal of Neuroscience.16(11): 3630–3640.doi:10.1523/JNEUROSCI.16-11-03630.1996.PMC6578841.PMID8642407.
  41. ^abWafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ (September 1996). "Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit".Molecular Pharmacology.50(3): 670–678.PMID8794909.
  42. ^AMA Department of Drugs: Drug Evaluations Subscription, American Medical Association, Chicago, IL, 1990.
  43. ^Knoben JE & Anderson PO (Eds): Handbook of Clinical Drug Data, 6th. Drug Intelligence Publications, Inc, Hamilton, IL, 1988.
  44. ^abcd"Product Information: Lasix(R), furosemide"(PDF).Aventis Pharmaceuticals, Bridgewater, NJ.U.S. Food and Drug Administration. 2004.
  45. ^abcdeGilman AG, Rall TW, Nies AS, et al. (1990).Goodman and Gilman's The Pharmacological Basis of Therapeutics(8th ed.). New York, NY: Pergamon Press.
  46. ^abcdeKelly MR, Cutler RE, Forrey AW, Kimpel BM (February 1974). "Pharmacokinetics of orally administered furosemide".Clinical Pharmacology and Therapeutics.15(2): 178–186.doi:10.1002/cpt1974152178.PMID4812154.S2CID74223978.
  47. ^Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA (June 1982). "Furosemide disposition in cirrhosis".Clinical Pharmacology and Therapeutics.31(6): 719–725.doi:10.1038/clpt.1982.101.PMID7075120.S2CID27659838.
  48. ^Chaturvedi PR, O'Donnell JP, Nicholas JM, Shoenthal DR, Waters DH, Gwilt PR (March 1987). "Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure".International Journal of Clinical Pharmacology, Therapy, and Toxicology.25(3): 123–128.PMID3557737.
  49. ^Brater DC (1991). "Clinical pharmacology of loop diuretics".Drugs.41(Supplement 3): 14–22.doi:10.2165/00003495-199100413-00004.PMID1712712.S2CID41247401.
  50. ^Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krähenbühl S (December 2007)."Sublingual administration of furosemide: new application of an old drug".British Journal of Clinical Pharmacology.64(6): 804–809.doi:10.1111/j.1365-2125.2007.03035.x.PMC2198789.PMID17875188.
  51. ^AHFS Drug Information 2004. McEvoy GK, ed. Furosemide. American Society of Health-System Pharmacists; 2004: 2260-4.
  52. ^"Naming human medicines".Archivedfrom the original on 27 April 2010.Retrieved18 November2009.
  53. ^"COMMENTARY: New York Buckles and Allows Lasix Use".Los Angeles Times.28 May 1995.Retrieved22 January2022.
  54. ^Hinchcliff KW, Muir WW (January 2022)."Pharmacology of furosemide in the horse: a review".Journal of Veterinary Internal Medicine.5(4): 211–218.doi:10.1111/j.1939-1676.1991.tb00951.x.PMID1941755.
  55. ^Kittleson M,Kienle R (1998).Small Animal Cardiovascular Medicine.Mosby.ISBN978-0-8151-5140-1.
  56. ^"U.S. Racetracks to ban race-day Lasix in 2021".18 April 2019.

Further reading

[edit]
  • Aventis Pharma(1998).Lasix Approved Product Information.Lane Cove: Aventis Pharma Pty Ltd.
  • Forney B (2007).Understanding Equine Medications, Revised Edition (Horse Health Care Library).Eclipse Press.ISBN978-1-58150-151-3.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Furosemide&oldid=1243359167"